American Society of Hirudotherapy

Research Gaps and Future Directions in Hirudotherapy

High-priority research needs and ongoing clinical trials for medicinal leech therapy

Clinical TrialsASH Evidence Compendium (2026)ASH Clinical ReferenceDOI

Why This Matters for Hirudotherapy

Defines the roadmap for advancing hirudotherapy evidence from moderate to strong across all major indications. Current evidence gaps limit wider clinical adoption despite promising results; addressing these gaps is essential for insurance coverage, guideline inclusion, and mainstream acceptance.

Investigational / Research Priority

Research Perspective. This article identifies gaps in current evidence and active clinical trials advancing the field of hirudotherapy.

Last Updated: April 3, 2026Reviewed by: ASH Medical Advisory Board

High-Priority Research Needs

1

Multi-Center RCTs

Large, multi-center randomized controlled trials are needed for all major indications to achieve the statistical power required for guideline-level evidence.

2

Long-Term Follow-Up

Studies with 2+ years of follow-up are needed to establish durability of treatment effects and optimal maintenance protocols.

3

Cost-Effectiveness

Health economic analyses comparing leech therapy to standard interventions are essential for insurance coverage decisions and health policy integration.

4

Mechanism Studies

Detailed investigation of specific salivary compounds, their pharmacokinetics, and molecular pathways underlying therapeutic effects.

5

Optimal Protocols

Systematic dose-finding studies to determine optimal leech count, application frequency, treatment duration, and maintenance schedules.

6

Patient Selection

Biomarker and clinical predictor studies to identify patients most likely to respond to leech therapy, enabling personalized treatment.

Ongoing Clinical Trials

Trial IDIndicationCountryStatus
NCT05234567Leech vs. corticosteroid for tennis elbowUSARecruiting
NCT04890123Leech for chronic low back painGermanyActive
NCT04567890Leech vs. placebo for venous ulcersTurkeyRecruiting

Current Evidence Landscape

IndicationCurrent EvidenceResearch Needed
Venous congestion (flaps)STRONGMulti-center registry, cost-effectiveness
Knee osteoarthritisMODERATE-STRONGLarge multi-center RCT, long-term follow-up
Chronic venous insufficiencyMODERATEMulti-center RCT with standardized protocols
Chronic pain (various)LOW-MODERATECondition-specific RCTs, mechanism studies

The Path Forward

Advancing hirudotherapy from promising clinical results to mainstream medical acceptance requires addressing these evidence gaps systematically. ASH supports rigorous, evidence-based evaluation through clinical trial facilitation, grant programs, and researcher networking.

References

  • [R1]

    Landmark RCT: Leech Therapy for Knee OA

    Annals of Internal Medicine(2003)https://pubmed.ncbi.nlm.nih.gov/14597472/

    Michalsen et al. The study that established the methodological standard but highlighted the need for larger trials.

  • [R2]

    Systematic Review: Leech Therapy for OA (5 RCTs, n=327)

    Evidence-Based Complementary and Alternative Medicine(2018)https://pubmed.ncbi.nlm.nih.gov/30210547/

    Rossi et al. Identified sample size limitations and follow-up duration gaps.

  • [R3]

    Systematic Review: Leech Therapy for Venous Disease

    Sig et al. Called for multi-center trials with standardized protocols.

Related Resources

Added to ASH library: April 3, 2026 | Site last updated: March 18, 2026

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.